3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
13
Carcinoma, Ovarian Epithelial
7
Prostatic Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Esophageal Neoplasms
1
Interventions
Specimen Handling
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
5
Nivolumab
4
Carboplatin
4
Biopsy
4
pembrolizumab
2
olaparib
2
ceralasertib
2
Taxes
2
trastuzumab deruxtecan
1
sargramostim
1
rucaparib
1
ribociclib
1
rebastinib
1
pelcitoclax
1
pamiparib
1
durvalumab
1
cobimetinib
1
cediranib
1
cabozantinib
1
belinostat
1
atezolizumab
1
X-Rays
1
Tissue Banks
1
TIC10 compound
1
Ipilimumab
1
Immunoglobulin G
1
Ifosfamide
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinosarcoma
×
rucaparib
×
Gynecologic
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts